Kamoto, S.; Shinada, M.; Kato, D.; Yoshimoto, S.; Ikeda, N.; Tsuboi, M.; Yoshitake, R.; Eto, S.; Hashimoto, Y.; Takahashi, Y.;
et al. Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma. Cells 2020, 9, 2529.
https://doi.org/10.3390/cells9112529
AMA Style
Kamoto S, Shinada M, Kato D, Yoshimoto S, Ikeda N, Tsuboi M, Yoshitake R, Eto S, Hashimoto Y, Takahashi Y,
et al. Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma. Cells. 2020; 9(11):2529.
https://doi.org/10.3390/cells9112529
Chicago/Turabian Style
Kamoto, Satoshi, Masahiro Shinada, Daiki Kato, Sho Yoshimoto, Namiko Ikeda, Masaya Tsuboi, Ryohei Yoshitake, Shotaro Eto, Yuko Hashimoto, Yosuke Takahashi,
and et al. 2020. "Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma" Cells 9, no. 11: 2529.
https://doi.org/10.3390/cells9112529
APA Style
Kamoto, S., Shinada, M., Kato, D., Yoshimoto, S., Ikeda, N., Tsuboi, M., Yoshitake, R., Eto, S., Hashimoto, Y., Takahashi, Y., Chambers, J., Uchida, K., Kaneko, M. K., Fujita, N., Nishimura, R., Kato, Y., & Nakagawa, T.
(2020). Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma. Cells, 9(11), 2529.
https://doi.org/10.3390/cells9112529